Mednax, Inc (MD) Receives $57.43 Average Target Price from Analysts
Mednax, Inc (NYSE:MD) has been given a consensus recommendation of “Hold” by the fourteen analysts that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $57.43.
Several equities analysts recently commented on the company. Stephens upgraded Mednax from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $55.00 to $68.00 in a research report on Thursday, June 22nd. Stifel Nicolaus cut their target price on Mednax from $65.00 to $58.00 and set a “hold” rating for the company in a research report on Thursday, May 25th. Mizuho cut their target price on Mednax from $64.00 to $58.00 and set a “neutral” rating for the company in a research report on Tuesday, May 30th. BidaskClub upgraded Mednax from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 13th. Finally, Jefferies Group LLC set a $46.00 target price on Mednax and gave the stock a “hold” rating in a research report on Sunday, July 30th.
COPYRIGHT VIOLATION WARNING: “Mednax, Inc (MD) Receives $57.43 Average Target Price from Analysts” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/10/mednax-inc-md-receives-57-43-average-target-price-from-analysts.html.
Shares of Mednax (MD) traded up 0.84% on Tuesday, reaching $41.98. The company had a trading volume of 802,296 shares. Mednax has a 12 month low of $41.20 and a 12 month high of $72.13. The firm has a market capitalization of $3.87 billion, a PE ratio of 13.37 and a beta of 0.40. The company’s 50-day moving average is $45.56 and its 200 day moving average is $58.00.
Mednax (NYSE:MD) last posted its earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.04. The business had revenue of $843 million during the quarter, compared to the consensus estimate of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. Mednax’s revenue was up 9.2% on a year-over-year basis. During the same quarter last year, the company earned $1.03 EPS. Equities analysts forecast that Mednax will post $3.31 earnings per share for the current year.
In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,969 shares of Mednax stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the completion of the transaction, the director now owns 18,072 shares in the company, valued at approximately $1,040,405.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Mn Services Vermogensbeheer B.V. increased its stake in shares of Mednax by 4.4% in the 1st quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock valued at $158,000 after buying an additional 102 shares during the period. Shell Asset Management Co. increased its stake in shares of Mednax by 8.4% in the 1st quarter. Shell Asset Management Co. now owns 15,570 shares of the company’s stock valued at $1,080,000 after buying an additional 1,200 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Mednax by 18.2% in the 1st quarter. Russell Investments Group Ltd. now owns 66,541 shares of the company’s stock valued at $4,618,000 after buying an additional 10,227 shares during the period. Sumitomo Mitsui Asset Management Company LTD increased its stake in shares of Mednax by 9.7% in the 1st quarter. Sumitomo Mitsui Asset Management Company LTD now owns 6,980 shares of the company’s stock valued at $484,000 after buying an additional 616 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its stake in shares of Mednax by 1.6% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 32,545 shares of the company’s stock valued at $2,258,000 after buying an additional 500 shares during the period.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.